Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)

N/A

Report date: 2024/12/23 11:18:22

Base Information

Drug NameAnti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)
Drug Alias NameBCMA-CD38 Bispecific CAR-Modified T CellsBCMA-CD38 bispecific CAR-T cells
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsB-cell maturation protein modulators
TargetsLymphocyte differentiation antigen CD38B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShengyan Pharmaceutical Technology
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Union HospitalShengyan Pharmaceutical Technology
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A